Pfizer (PFE +0.5%) will host a conference call
on Friday, May 15, at 10:00 am ET to review its Duchenne muscular
dystrophy (DMD) data presentation at the American Society of Gene and
Cell Therapy Annual Meeting.
The company’s candidate is gene therapy PF-06939926. In June 2019, it presented initial Phase 1b data on six boys with DMD that underwhelmed investors.
A 99-subject Phase 3 clinical trial is set to begin any time.
https://seekingalpha.com/news/3572233-pfizer-to-review-duchenne-gene-therapy-data-may-15
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.